Human carcinoma-associated mesenchymal stem cells promote ovarian cancer chemotherapy resistance via a BMP4/HH signaling loop

Oncotarget

Volumn 7, Issue 6, 2016, Pages 6916-6932

  Coffman, Lan G ^a   Choi, Yun Jung ^a   McLean, Karen ^b   Allen, Benjamin L ^a   Di Magliano, Marina Pasca ^a,b   Buckanovich, Ronald J ^a,b  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

Author keywords

BMP4; Hedgehog; Mesenchymal stem cell; Ovarian cancer; Tumor microenvironment

Indexed keywords

BETA GALACTOSIDASE; BONE MORPHOGENETIC PROTEIN 4; CISPLATIN; SONIC HEDGEHOG PROTEIN; BMP4 PROTEIN, HUMAN; GUANOSINE TRIPHOSPHATASE ACTIVATING PROTEIN; RABGAP1L PROTEIN, MOUSE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BMP4 GENE; CANCER CHEMOTHERAPY; CARCINOGENESIS; CELL DIFFERENTIATION; CELL VIABILITY; CONTROLLED STUDY; ENZYME ACTIVITY; FEMALE; GENE EXPRESSION; GENE INDUCTION; HH GENE; HUMAN; HUMAN TISSUE; IN VITRO STUDY; IN VIVO STUDY; MESENCHYMAL STEM CELL; MOUSE; NONHUMAN; OVARY CANCER; POSITIVE FEEDBACK; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN SYNTHESIS; SIGNAL TRANSDUCTION; TREATMENT RESPONSE; ANIMAL; CELL PROLIFERATION; DRUG RESISTANCE; DRUG SCREENING; GENETICS; MESENCHYMAL STROMA CELL; METABOLISM; OVARIAN NEOPLASMS; PATHOLOGY; TUMOR CELL LINE; TUMOR MICROENVIRONMENT;

ANIMALS; BONE MORPHOGENETIC PROTEIN 4; CELL LINE, TUMOR; CELL PROLIFERATION; DRUG RESISTANCE, NEOPLASM; FEMALE; GTPASE-ACTIVATING PROTEINS; HEDGEHOG PROTEINS; HUMANS; MESENCHYMAL STROMAL CELLS; OVARIAN NEOPLASMS; SIGNAL TRANSDUCTION; TUMOR MICROENVIRONMENT; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84980716932     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.6870     Document Type: Article

References (58)

1. Surveillance E, and End Results (SEER) Program (www.seer.cancer.gov) Research Data (1973-2010), National Cancer Institute, DCCPS, Surveillance Research Program, Surveillance Systems Branch, released April 2013, based on the November 2012 submission.
2. Nieman KM, Kenny HA, Penicka CV, Ladanyi A, Buell-Gutbrod R, Zillhardt MR, Romero IL, Carey MS, Mills GB, Hotamisligil GS, Yamada SD, Peter ME, Gwin K, et al. Adipocytes promote ovarian cancer metastasis and provide energy for rapid tumor growth. Nature medicine. 2011; 17:1498-1503.
3. Xu L, Deng Q, Pan Y, Peng M, Wang X, Song L, Xiao M and Wang Z. Cancer-associated fibroblasts enhance the migration ability of ovarian cancer cells by increasing EZH2 expression. International journal of molecular medicine. 2014; 33:91-96.
4. Thibault B, Castells M, Delord JP and Couderc B. Ovarian cancer microenvironment: implications for cancer dissemination and chemoresistance acquisition. Cancer metastasis reviews. 2014; 33:17-39. doi:10.1007/s10555-013-9456-2.
5. Yeung TL, Leung CS, Wong KK, Samimi G, Thompson MS, Liu J, Zaid TM, Ghosh S, Birrer MJ and Mok SC. TGF-beta modulates ovarian cancer invasion by upregulating CAF-derived versican in the tumor microenvironment. Cancer research. 2013; 73:5016-5028.
6. Yang X, Hou J, Han Z, Wang Y, Hao C, Wei L and Shi Y. One cell, multiple roles: contribution of mesenchymal stem cells to tumor development in tumor microenvironment. Cell & bioscience. 2013; 3:5.
7. Barcellos-de-Souza P, Gori V, Bambi F and Chiarugi P. Tumor microenvironment: bone marrow-mesenchymal stem cells as key players. Biochimica et biophysica acta. 2013; 1836:321-335.
8. Jung Y, Kim JK, Shiozawa Y, Wang J, Mishra A, Joseph J, Berry JE, McGee S, Lee E, Sun H, Wang J, Jin T, Zhang H, et al. Recruitment of mesenchymal stem cells into prostate tumours promotes metastasis. Nature communications. 2013; 4:1795.
9. Garcia MG, Bayo J, Bolontrade MF, Sganga L, Malvicini M, Alaniz L, Aquino JB, Fiore E, Rizzo MM, Rodriguez A, Lorenti A, Andriani O, Podhajcer O, et al. Hepatocellular carcinoma cells and their fibrotic microenvironment modulate bone marrow-derived mesenchymal stromal cell migration in vitro and in vivo. Molecular pharmaceutics. 2011; 8:1538-1548.
10. Birnbaum T, Roider J, Schankin CJ, Padovan CS, Schichor C, Goldbrunner R and Straube A. Malignant gliomas actively recruit bone marrow stromal cells by secreting angiogenic cytokines. Journal of neuro-oncology. 2007; 83:241-247.
11. da Silva Meirelles L, Chagastelles PC and Nardi NB. Mesenchymal stem cells reside in virtually all post-natal organs and tissues. Journal of cell science. 2006; 119:2204-2213.
12. Crisan M, Yap S, Casteilla L, Chen CW, Corselli M, Park TS, Andriolo G, Sun B, Zheng B, Zhang L, Norotte C, Teng PN, Traas J, et al. A perivascular origin for mesenchymal stem cells in multiple human organs. Cell stem cell. 2008; 3:301-313.
13. Kim SH, Bang SH, Park SA, Kang SY, Park KD, Oh IU, Yoo SH, Kim H, Kim CH and Baek SY. Character comparison of abdomen-derived and eyelid-derived mesenchymal stem cells. Cell proliferation. 2013; 46:291-299.
14. McLean K, Gong Y, Choi Y, Deng N, Yang K, Bai S, Cabrera L, Keller E, McCauley L, Cho KR and Buckanovich RJ. Human ovarian carcinoma-associated mesenchymal stem cells regulate cancer stem cells and tumorigenesis via altered BMP production. The Journal of clinical investigation. 2011; 121:3206-3219.
15. Dominici M, Le Blanc K, Mueller I, Slaper-Cortenbach I, Marini F, Krause D, Deans R, Keating A, Prockop D and Horwitz E. Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. Cytotherapy. 2006; 8:315-317.
16. Verardo R, Piazza S, Klaric E, Ciani Y, Bussadori G, Marzinotto S, Mariuzzi L, Cesselli D, Beltrami AP, Mano M, Itoh M, Kawaji H, Lassmann T, et al. Specific mesothelial signature marks the heterogeneity of mesenchymal stem cells from high-grade serous ovarian cancer. Stem Cells. 2014; 32:2998-3011.
17. Lan Y and Jiang R. Sonic hedgehog signaling regulates reciprocal epithelial-mesenchymal interactions controlling palatal outgrowth. Development. 2009; 136:1387-1396.
18. Yauch RL, Gould SE, Scales SJ, Tang T, Tian H, Ahn CP, Marshall D, Fu L, Januario T, Kallop D, Nannini-Pepe M, Kotkow K, Marsters JC, et al. A paracrine requirement for hedgehog signalling in cancer. Nature. 2008; 455:406-410.
19. Liao X, Siu MK, Au CW, Wong ES, Chan HY, Ip PP, Ngan HY and Cheung AN. Aberrant activation of hedgehog signaling pathway in ovarian cancers: effect on prognosis, cell invasion and differentiation. Carcinogenesis. 2009; 30:131-140.
20. Steg AD, Bevis KS, Katre AA, Ziebarth A, Dobbin ZC, Alvarez RD, Zhang K, Conner M and Landen CN. Stem Cell Pathways Contribute to Clinical Chemoresistance in Ovarian Cancer. Clin Cancer Res. 2012; 18:869-881.
21. McCann CK, Growdon WB, Kulkarni-Datar K, Curley MD, Friel AM, Proctor JL, Sheikh H, Deyneko I, Ferguson JA, Vathipadiekal V, Birrer MJ, Borger DR, Mohapatra G, et al. Inhibition of Hedgehog signaling antagonizes serous ovarian cancer growth in a primary xenograft model. PloS one. 2011; 6:e28077.
22. Catenacci Dvt BN NSea. (2013). Final analysis of a Phase-IB/randomized Phase-II study of gemcitabine (G) plus placebo (P) or vismodegib (V), a hedgehog (Hh) pathway inhibitor, in patients (pts) with metastatic pancreatic cancer (PC): a University of Chicago Phase-II consortium study. ASCO.
23. Shin K, Lim A, Zhao C, Sahoo D, Pan Y, Spiekerkoetter E, Liao JC and Beachy PA. Hedgehog signaling restrains bladder cancer progression by eliciting stromal production of urothelial differentiation factors. Cancer cell. 2014; 26:521-533.
24. Bai CB, Auerbach W, Lee JS, Stephen D and Joyner AL. Gli2, but not Gli1, is required for initial Shh signaling and ectopic activation of the Shh pathway. Development. 2002; 129:4753-4761.
25. Collins MA, Bednar F, Zhang Y, Brisset JC, Galban S, Galban CJ, Rakshit S, Flannagan KS, Adsay NV and Pasca di Magliano M. Oncogenic Kras is required for both the initiation and maintenance of pancreatic cancer in mice. The Journal of clinical investigation. 2012; 122:639-653.
26. Lee J, Platt KA, Censullo P and Ruizi Altaba A. Gli1 is a target of Sonic hedgehog that induces ventral neural tube development. Development. 1997; 124:2537-2552.
27. Chen X, Horiuchi A, Kikuchi N, Osada R, Yoshida J, Shiozawa T and Konishi I. Hedgehog signal pathway is activated in ovarian carcinomas, correlating with cell proliferation: it's inhibition leads to growth suppression and apoptosis. Cancer science. 2007; 98:68-76.
28. Silva IA, Bai S, McLean K, Yang K, Griffith K, Thomas D, Ginestier C, Johnston C, Kueck A, Reynolds RK, Wicha MS and Buckanovich RJ. Aldehyde dehydrogenase in combination with CD133 defines angiogenic ovarian cancer stem cells that portend poor patient survival. Cancer Res. 2011; 71:3991-4001.
29. Sofen H, Gross KG, Goldberg LH, Sharata H, Hamilton TK, Egbert B, Lyons B, Hou J and Caro I. A phase II, multicenter, open-label, 3-cohort trial evaluating the efficacy and safety of vismodegib in operable basal cell carcinoma. Journal of the American Academy of Dermatology. 2015; 73:99-105.e1. doi:10.1016/j.jaad.2015.03.013.
30. Samkari A, White J and Packer R. SHH inhibitors for the treatment of medulloblastoma. Expert review of neurotherapeutics. 2015:1-8.
31. Geeraert P, Williams JS and Brownell I. Targeting the hedgehog pathway to treat basal cell carcinoma. Journal of drugs in dermatology : JDD. 2013; 12:519-523.
32. Hwang RF, Moore TT, Hattersley MM, Scarpitti M, Yang B, Devereaux E, Ramachandran V, Arumugam T, Ji B, Logsdon CD, Brown JL and Godin R. Inhibition of the hedgehog pathway targets the tumor-associated stroma in pancreatic cancer. Molecular cancer research. 2012; 10:1147-1157.
33. Lee JJ, Perera RM, Wang H, Wu DC, Liu XS, Han S, Fitamant J, Jones PD, Ghanta KS, Kawano S, Nagle JM, Deshpande V, Boucher Y, et al. Stromal response to Hedgehog signaling restrains pancreatic cancer progression. Proceedings of the National Academy of Sciences of the United States of America. 2014; 111:E3091-3100.
34. Chen M, Carkner R and Buttyan R. The hedgehog/Gli signaling paradigm in prostate cancer. Expert review of endocrinology & metabolism. 2011; 6:453-467.
35. Levina E, Chen M, Carkner R, Shtutman M and Buttyan R. Paracrine Hedgehog increases the steroidogenic potential of prostate stromal cells in a Gli-dependent manner. The Prostate. 2012; 72:817-824.
36. Michelle L. Infinity Pharma halts pancreatic cancer trial. Boston Business J. 2012.
37. Berlin J, Bendell JC, Hart LL, Firdaus I, Gore I, Hermann RC, Mulcahy MF, Zalupski MM, Mackey HM, Yauch RL, Graham RA, Bray GL and Low JA. A randomized phase II trial of vismodegib versus placebo with FOLFOX or FOLFIRI and bevacizumab in patients with previously untreated metastatic colorectal cancer. Clin Cancer Res. 2013; 19:258-267.
38. Kaye SB, Fehrenbacher L, Holloway R, Amit A, Karlan B, Slomovitz B, Sabbatini P, Fu L, Yauch RL, Chang I and Reddy JC. A phase II, randomized, placebo-controlled study of vismodegib as maintenance therapy in patients with ovarian cancer in second or third complete remission. Clin Cancer Res. 2012; 18:6509-6518.
39. Varjosalo M and Taipale J. Hedgehog: functions and mechanisms. Genes & development. 2008; 22:2454-2472.
40. Yang L, He J, Huang S, Zhang X, Bian Y, He N, Zhang H and Xie J. Activation of hedgehog signaling is not a frequent event in ovarian cancers. Molecular Cancer. 2009; 8:1-5.
41. Bhattacharya R, Kwon J, Ali B, Wang E, Patra S, Shridhar V and Mukherjee P. Role of hedgehog signaling in ovarian cancer. Clin Cancer Res. 2008; 14.
42. Theriault BL, Shepherd TG, Mujoomdar ML and Nachtigal MW. BMP4 induces EMT and Rho GTPase activation in human ovarian cancer cells. Carcinogenesis. 2007; 28:1153-1162.
43. Shepherd TG, Theriault BL and Nachtigal MW. Autocrine BMP4 signalling regulates ID3 proto-oncogene expression in human ovarian cancer cells. Gene. 2008; 414:95-105.
44. Choi YJ, Ingram PN, Yang K, Coffman L, Iyengar M, Bai S, Thomas DG, Yoon E and Buckanovich RJ. Identifying an ovarian cancer cell hierarchy regulated by bone morphogenetic protein 2. Proceedings of the National Academy of Sciences of the United States of America. 2015.
45. Liu S, Ginestier C, Ou SJ, Clouthier SG, Patel SH, Monville F, Korkaya H, Heath A, Dutcher J, Kleer CG, Jung Y, Dontu G, Taichman R, et al. Breast cancer stem cells are regulated by mesenchymal stem cells through cytokine networks. Cancer Res. 2011; 71:614-624.
46. So KA, Min KJ, Hong JH and Lee JK. Interleukin-6 expression by interactions between gynecologic cancer cells and human mesenchymal stem cells promotes epithelial-mesenchymal transition. Int J Oncol. 2015; 47:1451-1459.
47. Castells M, Milhas D, Gandy C, Thibault B, Rafii A, Delord JP and Couderc B. Microenvironment mesenchymal cells protect ovarian cancer cell lines from apoptosis by inhibiting XIAP inactivation. Cell death & disease. 2013; 4:e887.
48. Lis R, Touboul C, Mirshahi P, Ali F, Mathew S, Nolan DJ, Maleki M, Abdalla SA, Raynaud CM, Querleu D, Al-Azwani E, Malek J, Mirshahi M, et al. Tumor associated mesenchymal stem cells protects ovarian cancer cells from hyperthermia through CXCL12. Int J Cancer. 2011; 128:715-725.
49. Touboul C, Lis R, Al Farsi H, Raynaud CM, Warfa M, Althawadi H, Mery E, Mirshahi M and Rafii A. Mesenchymal stem cells enhance ovarian cancer cell infiltration through IL6 secretion in an amniochorionic membrane based 3D model. J Transl Med. 2013; 11:28.
50. Yang Y, Bucan V, Baehre H, von der Ohe J, Otte A and Hass R. Acquisition of new tumor cell properties by MSC-derived exosomes. Int J Oncol. 2015; 47:244-252.
51. Yang Y, Otte A and Hass R. Human mesenchymal stroma/stem cells exchange membrane proteins and alter functionality during interaction with different tumor cell lines. Stem Cells Dev. 2015; 24:1205-1222.
52. Spaeth EL, Dembinski JL, Sasser AK, Watson K, Klopp A, Hall B, Andreeff M and Marini F. Mesenchymal stem cell transition to tumor-associated fibroblasts contributes to fibrovascular network expansion and tumor progression. PLoS One. 2009; 4:e4992.
53. Stagg J and Galipeau J. Mechanisms of immune modulation by mesenchymal stromal cells and clinical translation. Curr Mol Med. 2013; 13:856-867.
54. Coffman L, Mooney C, Lim J, Bai S, Silva I, Gong Y, Yang K and Buckanovich RJ. Endothelin receptor-A is required for the recruitment of antitumor T cells and modulates chemotherapy induction of cancer stem cells. Cancer biology & therapy. 2013; 14:184-192.
55. Schneider CA, Rasband WS and Eliceiri KW. NIH Image to ImageJ:25 years of image analysis. Nature methods. 2012; 9:671-675.
56. Lim JJ, Yang K, Taylor-Harding B, Wiedemeyer WR and Buckanovich RJ. VEGFR3 inhibition chemosensitizes ovarian cancer stemlike cells through down-regulation of BRCA1 and BRCA2. Neoplasia. 2014; 16:343-353 e341-342.
57. Lee MJ, Hatton BA, Villavicencio EH, Khanna PC, Friedman SD, Ditzler S, Pullar B, Robison K, White KF, Tunkey C, LeBlanc M, Randolph-Habecker J, Knoblaugh SE, et al. Hedgehog pathway inhibitor saridegib (IPI-926) increases lifespan in a mouse medulloblastoma model. Proceedings of the National Academy of Sciences of the United States of America. 2012; 109:7859-7864.
58. Pulaski HL, Spahlinger G, Silva IA, McLean K, Kueck AS, Reynolds RK, Coukos G, Conejo-Garcia JR and Buckanovich RJ. Identifying alemtuzumab as an anti-myeloid cell antiangiogenic therapy for the treatment of ovarian cancer. Journal of translational medicine. 2009; 7:49.